EMERYVILLE, Calif. & DENVER--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) and ArrowMark Partners ("ArrowMark†) today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG LS, a joint venture (JV) between ArrowMark and Viking Global Investors ("Viking†). Under the terms of the license and services agreement, OmniAb will receive revenue for services performed as well as potential equity and ...

Summary of AbCellera Biologics (ABCL) FY Conference Call - June 09, 2025 Company Overview - **Company**: AbCellera Biologics (ABCL) - **Transition**: Shifted from a platform company to a clinical-stage biotech with two internally developed agents authorized for clinical trials [3][4] Key Points and Arguments Financial Position - **Liquidity**: Company has approximately $800 million in liquidity, allowing for continued investment in pipeline development [3] Pipeline Development - **Initial Molecules**: Focus on two molecules, ABCL635 and ABCL575, entering clinical trials in Q3 2025 [3] - **Development Projects**: Over 20 development projects, with more than half targeting complex membrane protein targets [4] Target Selection Framework - **Framework Criteria**: Selection based on validated science, large commercial opportunities, differentiation, and clear development paths [5][6] ABCL635 Specifics - **Indication**: Targeting vasomotor symptoms (VMS) related to menopause, specifically hot flashes [8] - **Market Opportunity**: Estimated annual sales potential over $2 billion, with 30% of women experiencing moderate to severe VMS [10] - **Differentiation**: Antibody approach expected to have fewer safety issues compared to small molecules, with a preference for monthly dosing over daily oral administration [20][21] Market Dynamics - **Menopausal Hormone Therapy (MHT)**: Approximately 40 million women in the U.S. are of menopausal age, with 30% experiencing moderate to severe VMS. About 50% seek treatment, but 20% are contraindicated for MHT [25][26][27] - **Commercial Market**: Significant opportunity exists for alternatives to MHT, especially for the 1.2 million women contraindicated for MHT [28] ABCL575 Overview - **Mechanism**: Targets OX40 ligand, which mediates T cell expansion and survival, potentially offering safety advantages over OX40 receptor targeting [35] - **Indication**: Initially exploring atopic dermatitis, a large unmet medical need with existing successful treatments like Dupixent [38] Competitive Landscape - **Dupixent Comparison**: Dupixent generates $8 billion in sales but has limitations in patient response rates, indicating a potential market for alternative therapies like ABCL575 [41] Clinical Trials and Future Plans - **Phase One Trials**: Expected to start dosing in Q3 2025, with initial data anticipated in the first half of 2026 [49][50] - **Partnership Strategy**: ABCL635 is likely to be advanced independently, while ABCL575 may be better suited for partnership due to its broader indication potential [54][60] Legacy Business and Partnerships - **Ongoing Partnerships**: Continued investment in partnerships, including a recent collaboration with AbbVie on T cell engagers [61] - **GMP Facility**: Investment in a GMP facility expected to be operational by the end of the year, supporting clinical trial material production [62] Additional Important Content - **Patient Preferences**: Surveys indicate a preference for injectable treatments over daily oral medications among menopausal women [21][23] - **Market Segmentation**: There is room for both biologics and oral treatments in the market, with patient choice being a significant factor [32] This summary encapsulates the key insights from the conference call, highlighting the strategic direction, market opportunities, and clinical development plans of AbCellera Biologics.